🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the fight against increasingly resistant strains of the bacteria, according to researchers.

An International Public Health Issue

The sexually transmitted infection are escalating worldwide, with data suggesting more than 82 million infections each year. Particularly high rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary advancement in the face of growing infection rates, escalating drug resistance and the highly restricted treatment choices currently available.”

Public health authorities are increasingly worried about the rise in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program showed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the US FDA in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers believe that focused deployment of this new drug will help delay the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, also received approval in close succession. This drug, which is employed against UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the drug firm its industry partner to bring it to fruition.

“This authorization marks a significant shift in the management of highly resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

Based on data detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This puts it on an comparable level with the typical regimen, which involves two antibiotics. The study enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, the non-profit has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Clinicians on the front lines have expressed positive views. Access to a easy-to-administer therapy such as this is described as a "critical tool" for public health efforts. This is viewed as essential to lessen the impact of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.